FLT3-MUTATED ACUTE MYELOID LEUKEMIA OUTCOMES IN A NORTHEAST BRAZILIAN UNIVERSITY HOSPITAL

Authors

  • Hercules Amorim Mota Segundo Walter Cantídio University Hospital https://orcid.org/0009-0000-1494-078X
  • Lara Facundo de Alencar Araripe Walter Cantídio University Hospital (HUWC-UFC)
  • Ana Vitoria Magalhães Chaves Walter Cantídio University Hospital (HUWC-UFC)
  • Paulo Henrique Mariano de Alencar Walter Cantídio University Hospital (HUWC-UFC)
  • Fernando Barroso Duarte Walter Cantídio University Hospital (HUWC-UFC)

DOI:

https://doi.org/10.46765/2675-374X.2024v5n1p225

Abstract

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 25-45% of new diagnoses of Acute myeloid leukemia. The addition of FLT3 inhibitors to conventional protocols improves overall survival in this condition. Objectives: To assess the incidence of FLT3 gene mutation among patients diagnosed with AML at Walter Cantídio University Hospital; Describe access to FLT3 inhibitors and bone marrow transplantation (BMT), and the overall survival of this group. Methodology: Retrospective evaluation of medical records of patients treated for AML between 2020 and 2022. Statistical analysis was performed using the Kaplan-Meier method to estimate survival probability. Results: 47 patients were diagnosed with AML during this period, of whom 17% had FLT3+ mutation. 3/8 patients accessed FLT3 inhibitors. The median survival with FLT3+ mutation was 9.1 months vs. 12.9 months in FLT3- (p = 0.196). The overall survival of AML patients was 30.9% at 2 years. 11/47 patients underwent allogeneic BMT. Conclusion: The addition of targeted therapies and BMT may contribute to reduce mortality in AML.  Elderly patients and those not undergoing HSCT have worse outcomes. 

Downloads

Published

05/12/2024

How to Cite

Amorim Mota Segundo, H., Facundo de Alencar Araripe, L., Magalhães Chaves, A. V., Mariano de Alencar, P. H., & Barroso Duarte, F. (2024). FLT3-MUTATED ACUTE MYELOID LEUKEMIA OUTCOMES IN A NORTHEAST BRAZILIAN UNIVERSITY HOSPITAL . JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 5(1), 225. https://doi.org/10.46765/2675-374X.2024v5n1p225

Most read articles by the same author(s)